Por favor, use este identificador para citar o enlazar este ítem: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7073
COVID-19 Fatality and Comorbidity Risk Factors among Diagnosed Patients in Mexico
Hiram Carreño
Patricio Solís
Acceso Abierto
Atribución-NoComercial-SinDerivadas
https://doi.org/10.1101/2020.04.21.20074591
https://www.medrxiv.org/content/10.1101/2020.04.21.20074591v1
As of April 18, 2020, 2.16 million patients in the world had been tested positive with Coronavirus (COVID-19) and 146,088 had died, which accounts for a case fatality rate of 6.76%. In Mexico, according to official statistics (April 18), 7,497 cases have been confirmed with 650 deaths, for a case fatality rate of 8.67%. These estimates, however, may not reflect the final fatality risk among COVID-19 confirmed patients, because they are based on cross-sectional counts of diagnosed and deceased patients, and therefore are not adjusted by time of exposure and right-censorship. In this paper we estimate fatality risks based on survival analysis methods, calculated from individual-level data on symptomatic patients confirmed with COVID-19 recently released by the Mexican Ministry of Health. The estimated fatality risk after 35 days of onset of symptoms is 12.38% (95% CI: 11.37-13.47). Fatality risks sharply rise with age, and significantly increase for males (59%) and individuals with comorbidities (38%-168%, depending on the disease). Two reasons may explain the high COVID-19 related fatality risk observed in Mexico, despite its younger age structure: the high selectivity and self-selectivity in testing and the high prevalence of chronic-degenerative diseases.
medRxiv and bioRxiv
25-04-2020
Preimpreso
www.medrxiv.org
Inglés
Epidemia COVID-19
Público en general
VIRUS RESPIRATORIOS
Versión publicada
publishedVersion - Versión publicada
Aparece en las colecciones: Artículos científicos

Cargar archivos: